MRNA's earnings and revenues surpass estimates in the fourth quarter of 2024. The company reiterates 2025 total revenue ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

You'll start out at Seaside Resort with several types of resources, but one that you should grab every day is Rubber. This resource is required for crafting an important item that unlocks a ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., February 12, 2025. REUTERS/Brendan McDermid/File Photo The S&P 500 advanced on Thursday, with gains in ...

At close: 7 February at 7:30:54 pm GMT+1 ...

At close: February 10 at 4:00:00 p.m. EST ...